MedPath

PhaseII trial of Gemcitabine(G)and Platinam-doublet plus continuous maintenance Gemcitabine in untreated stage three/four squamous non-small cell lung cancer(NSCLC)

Not Applicable
Conditions
on-small cell lung cancer
Registration Number
JPRN-UMIN000011794
Lead Sponsor
Hiroshima University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
33
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patient having clear infection (2) Patient having hepatitis B with the activity (3) Serious complications (stroma-related pneumonia, bleeding tendency, control are poor a heart trouble, pulmonary fibrosis) The patient whom high blood pressure or diabetes have) (4) Patient having an active overlap cancer (under nondisease period five years) (5) Metastasis to brain patient having a symptom (6) Hydrothorax to need treatment, abdominal dropsy retention patient (7) Pericardial fluid retention patient (8) Patient having an anamnesis of drug allergies (9) A pregnant woman, a nursing girl and woman with the possibility (intention) of the pregnancy (10) principal investigator cases that are deemed inappropriate

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Progression Free Survival
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath